Pharmaceutical Executive-05-01-2015

Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.

Pharm Exec’s 9th annual Brand of the Year selection is Gilead Science’s back-to-back cures for HCV. We profile how both drugs reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations.

Gilead outlines its key access initiatives for its hepatitis C franchise.

What’s new in the growing field of global market access?

Tapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.

Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago

Tactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.

Edging through the complex terrain that is health technology assessment in Europe

Once focused mainly on generic medicines, Korea’s pharma sector has leveraged significant new investments in R&D to transform itself into a true player in the global market-with aspirations as a future top-tier contributor to new medicines innovation.